Search Results - "TASKAR, Kunal S"

Physiologically‐Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug–Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations by Taskar, Kunal S., Pilla Reddy, Venkatesh, Burt, Howard, Posada, Maria M., Varma, Manthena, Zheng, Ming, Ullah, Mohammed, Emami Riedmaier, Arian, Umehara, Ken‐ichi, Snoeys, Jan, Nakakariya, Masanori, Chu, Xiaoyan, Beneton, Maud, Chen, Yuan, Huth, Felix, Narayanan, Rangaraj, Mukherjee, Dwaipayan, Dixit, Vaishali, Sugiyama, Yuichi, Neuhoff, Sibylle

“…Physiologically‐based pharmacokinetic (PBPK) modeling has been extensively used to quantitatively translate in vitro data and evaluate temporal effects from…”
Get full text

Heterogeneous Blood-Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer by LOCKMAN, Paul R, MITTAPALLI, Rajendar K, SUYUN HUANG, PALMIERI, Diane, STEEG, Patricia S, SMITH, Quentin R, TASKAR, Kunal S, RUDRARAJU, Vinay, GRIL, Brunilde, BOHN, Kaci A, ADKINS, Chris E, ROBERTS, Amanda, THORSHEIM, Helen R, GAASCH, Julie A

“…Brain metastases of breast cancer appear to be increasing in incidence, confer significant morbidity, and threaten to compromise gains made in systemic…”
Get full text

Intestinal P‐gp and Putative Hepatic OATP1B Induction: International Transporter Consortium Perspective on Drug Development Implications by Zamek‐Gliszczynski, Maciej J., Patel, Mitesh, Yang, Xinning, Lutz, Justin D., Chu, Xiaoyan, Brouwer, Kim L. R., Lai, Yurong, Lee, Caroline A., Neuhoff, Sibylle, Paine, Mary F., Sugiyama, Yuichi, Taskar, Kunal S., Galetin, Aleksandra

“…There is an increasing interest in transporter induction (i.e., decreased systemic drug exposure due to increased efflux‐limited absorption or…”
Get full text

Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective by Kenna, J. Gerry, Taskar, Kunal S., Battista, Christina, Bourdet, David L., Brouwer, Kim L.R., Brouwer, Kenneth R., Dai, David, Funk, Christoph, Hafey, Michael J., Lai, Yurong, Maher, Jonathan, Pak, Y. Anne, Pedersen, Jenny M., Polli, Joseph W., Rodrigues, A. David, Watkins, Paul B., Yang, Kyunghee, Yucha, Robert W.

“…Bile salt export pump (BSEP) inhibition has emerged as an important mechanism that may contribute to the initiation of human drug‐induced liver injury (DILI)…”
Get full text

Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer by Taskar, Kunal S., Rudraraju, Vinay, Mittapalli, Rajendar K., Samala, Ramakrishna, Thorsheim, Helen R., Lockman, Julie, Gril, Brunilde, Hua, Emily, Palmieri, Diane, Polli, Joseph W., Castellino, Stephen, Rubin, Stephen D., Lockman, Paul R., Steeg, Patricia S., Smith, Quentin R.

“…ABSTRACT Purpose Lapatinib, a small molecule EGFR/HER2 inhibitor, partially inhibits the outgrowth of HER2+ brain metastases in preclinical models and in a…”
Get full text

Physiologically‐based pharmacokinetic modeling of prominent oral contraceptive agents and applications in drug–drug interactions by Lewis, Gareth J., Ahire, Deepak, Taskar, Kunal S.

“…Considerable interest remains across the pharmaceutical industry and regulatory landscape in capabilities to model oral contraceptives (OCs), whether combined…”
Get full text

Robust physiologically based pharmacokinetic model of rifampicin for predicting drug–drug interactions via P‐glycoprotein induction and inhibition in the intestine, liver, and kidney by Asaumi, Ryuta, Nunoya, Ken‐ichi, Yamaura, Yoshiyuki, Taskar, Kunal S., Sugiyama, Yuichi

“…P‐glycoprotein (P‐gp) is an efflux transporter that plays an important role in the pharmacokinetics of its substrate, and P‐gp activities can be altered by…”
Get full text

Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug by Salem, Farzaneh, Nimavardi, Ali, Mudunuru, Jennypher, Tompson, Debra, Bloomer, Jackie, Turner, David B., Taskar, Kunal S.

“…In celiac disease (CeD), gastrointestinal CYP3A4 abundance and morphology is affected by the severity of disease. Therefore, exposure to CYP3A4 substrates and…”
Get full text

Vorinostat Inhibits Brain Metastatic Colonization in a Model of Triple-Negative Breast Cancer and Induces DNA Double-Strand Breaks by PALMIERI, Diane, LOCKMAN, Paul R, TASKAR, Kunal S, RUDRARAJU, Vinay, MITTAPALLI, Rajendar K, GAASCH, Julie A, BOHN, Kaci A, THORSHEIM, Helen R, LIEWEHR, David J, DAVIS, Sean, REILLY, John F, WALKER, Robert, THOMAS, Fancy C, BRONDER, Julie L, FEIGENBAUM, Lionel, STEINBERG, Seth M, CAMPHAUSEN, Kevin, MELTZER, Paul S, RICHON, Victoria M, SMITH, Quentin R, STEEG, Patricia S, HUA, Emily, HERRING, Jeanne, HARGRAVE, Elizabeth, JOHNSON, Matthew, FLORES, Natasha, YONGZHEN QIAN, VEGA-VALLE, Eleazar

“…Purpose: As chemotherapy and molecular therapy improve the systemic survival of breast cancer patients, the incidence of brain metastases increases. Few…”
Get full text

Estimation of the Unbound Brain Concentration of P‑Glycoprotein Substrates or Nonsubstrates by a Serial Cerebrospinal Fluid Sampling Technique in Rats by Mariappan, T. Thanga, Kurawattimath, Vishwanath, Gautam, Shashyendra Singh, Kulkarni, Chetan P, Kallem, Rajareddy, Taskar, Kunal S, Marathe, Punit H, Mandlekar, Sandhya

“…The unbound concentration in plasma drives the transport of the drug into the brain, and the unbound drug concentration in the central nervous system (CNS)…”
Get full text

When special populations intersect with drug–drug interactions: Application of physiologically‐based pharmacokinetic modeling in pregnant populations by Sychterz, Caroline, Galetin, Aleksandra, Taskar, Kunal S.

“…Pregnancy results in significant physiological changes that vary across trimesters and into the postpartum period, and may result in altered disposition of…”
Get full text

Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites by Patel, Mitesh, Taskar, Kunal S., Zamek-Gliszczynski, Maciej J.

“…This review provides a practical clinical perspective on the relevance of hepatic transporters in pharmacokinetics and drug‐drug interactions (DDIs). Special…”
Get full text

Clinical Relevance of Hepatic and Renal P‐gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective by Taskar, Kunal S., Yang, Xinning, Neuhoff, Sibylle, Patel, Mitesh, Yoshida, Kenta, Paine, Mary F., Brouwer, Kim L.R., Chu, Xiaoyan, Sugiyama, Yuichi, Cook, Jack, Polli, Joseph W., Hanna, Imad, Lai, Yurong, Zamek‐Gliszczynski, Maciej

“…The role of P‐glycoprotein (P‐gp) and breast cancer resistance protein (BCRP) in drug–drug interactions (DDIs) and limiting drug absorption as well as…”
Get full text

Clinical Extrapolation of the Effects of Dolutegravir and Other HIV Integrase Inhibitors on Folate Transport Pathways by Zamek-Gliszczynski, Maciej J, Zhang, Xuexiang, Mudunuru, Jennypher, Du, Yewei, Chen, Jian-Lu, Taskar, Kunal S, Huang, Jane, Huang, Yong, Romach, Elizabeth H

“…Preliminary analysis of ongoing birth surveillance study identified evidence of potential increased risk for neural tube defects (NTDs) in newborns associated…”
Get full text

Unmasking the Role of Uptake Transporters for Digoxin Uptake Across the Barriers of the Central Nervous System in Rat by Taskar, Kunal S, Mariappan, T Thanga, Kurawattimath, Vishwanath, Singh Gautam, Shashyendra, Radhakrishna Mullapudi, TV, Sridhar, Srikanth K, Kallem, Raja Reddy, Marathe, Punit, Mandlekar, Sandhya

“…The role of uptake transporter (organic anion–transporting polypeptide [Oatp]) in the disposition of a P-glycoprotein (P-gp) substrate (digoxin) at the…”
Get full text

Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective by Reddy, Micaela B, Cabalu, Tamara D, de Zwart, Loeckie, Ramsden, Diane, Dowty, Martin E, Taskar, Kunal S, Badée, Justine, Bolleddula, Jayaprakasam, Boulu, Laurent, Fu, Qiang, Kotsuma, Masakatsu, Leblanc, Alix F, Lewis, Gareth, Liang, Guiqing, Parrott, Neil, Pilla Reddy, Venkatesh, Prakash, Chandra, Shah, Kushal, Umehara, Kenichi, Mukherjee, Dwaipayan, Rehmel, Jessica, Hariparsad, Niresh

“…Physiologically-based pharmacokinetic (PBPK) modeling offers a viable approach to predict induction drug-drug interactions (DDIs) with the potential to…”
Get full text

Industrial Perspective on the Benefits Realized From the FDA’s Model‐Informed Drug Development Paired Meeting Pilot Program by Galluppi, Gerald R., Brar, Satjit, Caro, Luzelena, Chen, Yuan, Frey, Nicolas, Grimm, Hans Peter, Rudd, Deanne Jackson, Li, Chi‐Chung, Magee, Mindy, Mukherjee, Arnab, Nagao, Lee, Purohit, Vivek S., Roy, Amit, Salem, Ahmed Hamed, Sinha, Vikram, Suleiman, Ahmed A., Taskar, Kunal S., Upreti, Vijay V., Weber, Benjamin, Cook, Jack

Get full text

Development of a physiologically based pharmacokinetic model of fostemsavir and its pivotal application to support dosing in pregnancy by Salem, Farzaneh, Nguyen, Dung, Bush, Mark, Moore, Katy P, Mudunuru, Jennypher, Stamatopoulos, Konstantinos, Thakkar, Nilay, Taskar, Kunal S

“…It is critical to understand the impact of significant physiological changes during pregnancy on the extent of maternal and fetal drug exposure. Fostemsavir…”
Get full text

Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations by Patel, Aarti, Wilson, Robert, Harrell, Andrew W, Taskar, Kunal S, Taylor, Maxine, Tracey, Helen, Riddell, Kylie, Georgiou, Alex, Cahn, Anthony P, Marotti, Miriam, Hessel, Edith M

“…In vitro data for low-dose inhaled phosphoinositide 3-kinase delta inhibitor nemiralisib revealed that it was a substrate and a potent metabolism-dependent…”
Get full text

Intestinal P-gp and Putative Hepatic OATP1B Induction: ITC Perspective on Drug Development Implications by Zamek-Gliszczynski, Maciej J., Patel, Mitesh, Yang, Xinning, Lutz, Justin D., Chu, Xiaoyan, Brouwer, Kim L. R., Lai, Yurong, Lee, Caroline A., Neuhoff, Sibylle, Paine, Mary F., Sugiyama, Yuichi, Taskar, Kunal S., Galetin, Aleksandra

“…There is an increasing interest in transporter induction (i.e., decreased systemic drug exposure due to increased efflux-limited absorption or…”
Get full text